Solid Tumors clinical trials
Showing 201–250 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- SLV-324 Treatment of Metastatic Solid Tumors
- A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
- Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
- Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
- STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
- An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
- A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
- A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
- Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
- Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
- Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
- A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
- Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
- A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
- Study of GS-5319 in Adults With Solid Tumors
- Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
- A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
- Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
- Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
- A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
- A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
- A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- First in Human, Dose Escalation Study of AN4005
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
- Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
- FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
- Advanced or Recurrent Solid Tumors Treated With SHetA2
- Study of CHS-114 in Participants With Advanced Solid Tumors
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
- NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
- SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.